Press Release: Veterans Exploring Treatment Solutions (VETS) Applauds Texas on Passing the Largest Publicly Funded Psychedelic Research Investment in U.S. History
VETS celebrates the passage of the Texas Ibogaine Initiative—landmark legislation that allocates $100 million in public and private funding to study ibogaine-assisted therapy for PTSD, addiction, and TBI. This historic investment, driven in large part by VETS’ advocacy, positions Texas as a national leader in psychedelic research and veteran mental health care.
Press Release: Texas Launches Largest Publicly-Funded Psychedelic Research Initiative in History with $50 Million Investment in Ibogaine
Texas becomes the first state in the nation to invest in drug development trials for ibogaine, launching the largest publicly-funded psychedelic research initiative in history and offering new hope for those suffering from substance use, trauma, and brain injury.
Press Release: Veterans Exploring Treatment Solutions (VETS) Leads Legislative Day of Action in Support of AB 1103 at California State Capitol
VETS Advocacy Campaign Expands to California as Efforts for Access to Life-Changing Mental Health Treatments Continue
PRESS RELEASE: Veterans Exploring Treatment Solutions (VETS) Announces 4th Annual Torchbearer Ball to End Veteran Suicide
On November 15, 2025, the 4th Annual Torchbearer Ball returns to the iconic Hotel del Coronado. Hosted by Veterans Exploring Treatment Solutions (VETS), this black-tie gala gathers 600+ guests to honor veteran advocates, raise vital funds for psychedelic-assisted therapies, and advance the mission to end veteran suicide. This year’s Torchbearer Award will recognize filmmakers Jon Shenk and Bonni Cohen for their documentary In Waves and War, highlighting the healing journeys of Special Operations veterans.
- 7.8.2025
- Blog
A New Hope for Healing: Psilocybin Clinical Trial Now Open to Veterans
Thanks to the recent passage of SB5263, Washington State is developing a robust legal framework for Washington residents over the age of 21 to access psilocybin services. With it comes a clinical trial designed specifically for U.S. veterans.
- 7.2.2025
- News
Advocate reacts to Texas governor signing psychedelic research bill into law
An advocate featured by KXAN celebrates Texas’s new legislation as a turning point—allocating $50 million in public funding for ibogaine clinical trials to address PTSD, addiction, and brain injury. She highlights the significance of this support for veterans and first responders.
- 7.2.2025
- News
Why Veterans With PTSD Are Turning to Psychedelics
Veterans are increasingly exploring psychedelic treatments—like ketamine, ayahuasca, psilocybin, MDMA, and ibogaine—to heal from PTSD. These therapies tend to be used in guided, clinically-informed settings, with some programs even including spouses for shared healing. Although ibogaine remains illegal in the U.S., many veterans are traveling abroad, driven by promising early results
- 7.2.2025
- News
‘Psychedelics and the Texas Trip’ explores science & history behind state-funded research initiative
Texas recently approved $50 million in public funding, matched privately, to study ibogaine—a plant-derived psychedelic—as a potential treatment for PTSD, TBI, addiction, and related conditions. The initiative is facilitated through a public–private partnership and includes protections to ensure future therapy revenues fund veterans’ programs
- 7.2.2025
- News
Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing
Texas is the first state to fund clinical trials of ibogaine, investing $50 million in public funds to explore its potential for treating PTSD, addiction, and TBI—with future revenues supporting veterans’ programs.
- 7.2.2025
- News
Texas governor signs bill allocating up to $100 million in funding for psychedelics research
Texas has passed a landmark bill dedicating up to $100 million—half from public funds—to study ibogaine for conditions like PTSD, TBI, and addiction. A portion of future revenue will directly support veterans’ programs, marking a major step toward expanding access to psychedelic-assisted therapies.